Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...

The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...

Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

PBC is generally treated first line with ursodeoxycholic acid (UDCA), but the new entrants – including Ocaliva and elafibranor – are positioned as second-line therapies in patients who haven't ...

Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Prescription drugs can be administered in various ways. This includes oral (by mouth), enteral (into the gastrointestinal tract), mucosal (through a mucus membrane), and percutaneous (through the skin ...

Dozens of different medications can help treat high blood pressure (hypertension). These medications are called antihypertensives and are divided into many different categories, each of which ...